You are here: Industry Insights > Moleculin

News List

Moleculin Selects IQVIA Biotech to Advance COVID Treatment contractpharma
April 08, 2021
IQVIA to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.
Moleculin Announces Positive Interim Results in Adult Glioblastoma Clinical Trial americanpharmaceuticalreview
October 19, 2020
Moleculin Biotech announced additional preliminary data from the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, in patients with glioblastoma (GBM).
Moleculin Announces Antiviral Drug Candidates Demonstrate In Vitro Activity against HIV americanpharmaceuticalreview
October 10, 2020
Moleculin Biotech announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing in vitro activity in a range of infectious diseases.
In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus americanpharmaceuticalreview
July 28, 2020
Moleculin Biotech announced a second round of independent laboratory testing has confirmed the antiviral activity of WP1122 against coronavirus.
Moleculin Enters Agreement with Sterling Pharma contractpharma
July 16, 2020
Will produce WP1122 for potential treatment of COVID-19.
Moleculin, UTMB partner to study WP1122 for coronavirus pharmaceutical-technology
March 19, 2020
Moleculin Biotech has partnered with the University of Texas Medical Branch at Galveston (UTMB) to test its molecular inhibitors, including WP1122, to treat different viruses ...
Moleculin, UTMB Evaluate Inhibitors for Antiviral Properties contractpharma
March 18, 2020
Moleculin will supply the lead drug candidate, WP1122, and related inhibitors, as well as technical support.
Moleculin Announces Additional Positive Interim Results from Studies of Annamycin in AML americanpharmaceuticalreview
December 10, 2019
Moleculin Biotech announced additional positive interim safety and efficacy data from one of the Company's two ongoing open label ...
Moleculin Files for New Patents for Annamycin July 12, 2019
Moleculin Biotech announced it has filed new patents covering the production and reconstitution of Annamycin, which is c
Moleculin Announces Additional Positive Interim Results in Studies of Annamycin in AML in Europe americanpharmaceuticalreview
May 08, 2019
Moleculin Biotech announced additional positive interim safety and efficacy data from its ongoing open label, single arm Phase 1/2 study of Annamycin in Poland.

Previous page 1 2 Next page